Friday, February 17, 2023, San Francisco, California, 6:30 PM – 8:00 PM Pacific Time (9:30 PM – 11:00 PM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Urothelial Bladder Cancer

Part 3 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Genitourinary Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
6:15 PM – 6:30 PM — Registration
6:30 PM – 8:00 PM — Educational Dinner Meeting

Meeting Room
Yerba Buena – Salon 7 (Lower B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Matthew D Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Co-Leader, Bladder Cancer Center of Excellence
Associate Director, Translational Research
The Tisch Cancer Institute
New York, New York

Jonathan E Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W Ercklentz Chair
Memorial Sloan Kettering Cancer Center
New York, New York


Arlene Siefker-Radtke, MD
Professor
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Elisabeth I Heath, MD
Associate Center Director, Translational Sciences
Chair, Genitourinary Oncology Multidisciplinary Team
Professor of Oncology and Medicine
Hartmann Endowed Chair for Prostate Cancer Research
Director, Prostate Cancer Research
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan


This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
Program Schedule — Pacific Time
6:15 PM – 6:30 PM — Registration
6:30 PM – 8:00 PM — Educational Dinner Meeting

MODULE 1: Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC)

  • Selection of patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for pembrolizumab therapy
  • Key efficacy and safety data from the Phase III CheckMate 274 trial comparing nivolumab to placebo after radical surgery for high-risk muscle-invasive bladder cancer (MIBC)
  • Identification of candidates for adjuvant nivolumab and optimal integration of this agent into current clinical practice
  • Rates of pathologic complete response and other clinically relevant endpoints achieved in early trials of neoadjuvant anti-PD-1/PD-L1 antibody therapy for resectable MIBC
  • Mechanism of antitumor activity of the novel intravesical drug delivery system TAR-200; early data in MIBC
  • Ongoing studies of TAR-200 for NMIBC and MIBC (eg, SunRISe-1, SunRISe-2, SunRISe-4)
  • Other ongoing studies evaluating anti-PD-1/PD-L1 antibody-based approaches for nonmetastatic UBC (eg, POTOMAC, ALBAN, KEYNOTE-676, NIAGARA, ENERGIZE, VOLGA, KEYNOTE-866, KEYNOTE-905/EV-303)

MODULE 2: Current and Future Front-Line Treatment for Metastatic UBC (mUBC)

  • Current clinical role of atezolizumab or pembrolizumab as first-line treatment for mUBC; importance of chemotherapy eligibility and PD-L1 status in patient selection for this strategy
  • Appropriate incorporation of maintenance avelumab after front-line chemotherapy for mUBC
  • Biologic rationale for the investigation of anti-PD-1/PD-L1 antibodies in combination with novel therapies (eg, enfortumab vedotin, erdafitinib) for previously untreated mUBC
  • Emerging results from cohort K of the EV-103/KEYNOTE-869 study of first-line pembrolizumab in combination with enfortumab vedotin
  • Achievement of the primary endpoint in cohort K of the EV-103/KEYNOTE-869 study and potential clinical role of up-front pembrolizumab/enfortumab vedotin for patients with mUBC who are ineligible to receive cisplatin-based chemotherapy
  • Preliminary data with erdafitinib in combination with cetrelimab for patients with previously untreated mUBC with FGFR3 or FGFR2 genetic alterations

MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory mUBC

  • Clinical and biologic factors in the selection and sequencing of available therapies for patients with relapsed disease
  • Long-term outcomes with enfortumab vedotin for patients with progressive mUBC; appropriate integration into the treatment paradigm
  • Extended follow-up with the use of erdafitinib for patients with mUBC and FGFR3 or FGFR2 genetic alterations; current role in clinical practice
  • Principal findings with sacituzumab govitecan for progressive mUBC; optimal incorporation into disease management
  • Early results with sacituzumab govitecan combined with pembrolizumab for relapsed mUBC
  • Spectrum, incidence and severity of toxicities with enfortumab vedotin, erdafitinib and sacituzumab govitecan; mitigation and management strategies

MODULE 4: Novel Investigational Agents and Strategies in the Treatment of mUBC

  • Mechanism of action of the antibody-drug conjugate disitamab vedotin; efficacy and safety findings and ongoing evaluation in mUBC
  • Early activity and safety data with the combination of trastuzumab deruxtecan and nivolumab for HER2-expressing mUBC
  • Biologic rationale for the investigation of PARP inhibitors for mUBC; implications of recently reported studies of PARP inhibition (eg, BAYOU, ATLANTIS) for future research and patient care
  • Preliminary data with and ongoing studies of FGFR inhibitors beyond erdafitinib (eg, pemigatinib, futibatinib) for mUBC
  • Available data with and ongoing Phase III trials of anti-PD-1/PD-L1 antibodies combined with anti-CTLA-4 antibodies with or without chemotherapy for mUBC
  • Other promising agents and strategies under investigation for mUBC

Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of urothelial bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
  • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this strategy.
  • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for patients with metastatic urothelial bladder cancer (UBC).
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these therapies would be appropriate.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
  • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for NMIBC, MIBC and metastatic UBC.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr GalskyAdvisory Committee: Aileron Therapeutics Inc, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, BioMotiv, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Dracen Pharmaceuticals, Dragonfly Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Infinity Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Numab, Pfizer Inc, Seagen Inc, UroGen Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck. Dr RosenbergAdvisory Committee: Astellas, Seagen Inc, Tyra Biosciences; Consulting Agreements: Aadi Bioscience, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Imvax Inc, Infinity Pharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Lilly, Merck, Mirati Therapeutics Inc, Pfizer Inc, QED Therapeutics, Seagen Inc, Tyra Biosciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc; Honoraria: EMD Serono Inc, Pfizer Inc. Dr Siefker-RadtkeConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bristol-Myers Squibb Company, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IDEAYA Biosciences, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, Nektar, Seagen Inc, Taiho Oncology Inc; Contracted Research: Basilea Pharmaceutica Ltd, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Nektar, Takeda Pharmaceuticals USA Inc; Honoraria: Janssen Biotech Inc.

MODERATORElisabeth I Heath, MDAdvisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi; Consulting Agreement: Astellas; Contracted Research: Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, BioXcel Therapeutics Inc, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffman-La Roche Ltd, Five Prime Therapeutics Inc, Fortis Therapeutics, Gilead Sciences Inc, GlaxoSmithKline, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Merck, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Modra Pharmaceuticals, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Honoraria: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Genzyme Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Seagen Inc; Speakers Bureau: Sanofi; Nonrelevant Financial Relationship: Calibr.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MDDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Yerba Buena – Salon 7 (Lower B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2023 ASCO Genitourinary Cancers Symposium is taking place.

 
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of urothelial bladder cancer.

There is no fee to participate in this hybrid event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-Person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.